EXECUTIVE Committee

Dylan Burger, PhD (Ottawa, Ontario) - President

Dylan Burger (PhD, ISHF) is a Senior Scientist at the Ottawa Hospital Research Institute and Associate Professor at the University of Ottawa (Department of Cellular and Molecular Medicine). His research focuses on understanding the molecular underpinnings of diabetes and hypertension and their associated cardiovascular complications. In particularly he has been active in the study of extracellular vesicles as markers and mediators of vascular and renal injury for more than 10 years. He has authored more than 110 manuscripts and has received several awards including the 2016 Canadian Society of Nephrology New Investigator Lectureship and the 2018 University of Ottawa Department of Medicine PhD Scientist Award. He is the former Chair of Communications for the International Society of Hypertension. Dr. Burger is a founding member of The Lancet Commission on Hypertension and Associate Editor for the European Heart Journal and the Journal of Extracellular Vesicles.

Brad Urquhart, PhD (London, Ontario) – Past President

Brad Urquhart is Associate Professor in the Department of Physiology and Pharmacology and Associate Dean, Basic Medical Sciences Undergraduate Education at Western University. Brad has previously served on the CSPT scientific program committee and is currently the treasurer of CSPT. His research investigates mechanisms for variability in drug response and toxicity in kidney disease.

Thomas J. Velenosi PhD (Vancouver, British Columbia) – Treasurer

Dr. Velenosi received his PhD in pharmacology and toxicology from Western University. He completed his postdoctoral fellowship in the Laboratory of Metabolism at the National Cancer Institute (National Institutes of Health), and is currently an assistant professor in the UBC Faculty of Pharmaceutical Sciences. The Velenosi lab is focused at the intersection of pharmacology and metabolomics, using pharmacometabolomics to deepen our understanding of drug treatment response and toxicity during cancer therapy. His lab applies mass spectrometry-based metabolomics, lipidomics and stable-isotope metabolic flux analysis to identify and characterize biomarkers and therapeutic targets. Their approach is to determine the mechanisms of metabolic biomarker production and response to drug treatment using highly translational cancer models.